Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions

References

• Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity. 2014;41:694–707.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Bondy GP, Waisman D, et al. The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte. Blood. 1999;93:2730–2737.
   PubMed Web of Science ®Google Scholar
• Stefanelli T, Malesci A, De La Rue SA, et al. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmun Rev. 2008;7:364–369.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
   PubMed Web of Science ®Google Scholar
• Lobatón T, Vermeire S, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579–594.
   PubMed Web of Science ®Google Scholar
• Santamaria LF, Perez Soler MT, Hauser C, et al. Allergen specificity and endothelial transmigration of T cells in allergic contact dermatitis and atopic dermatitis are associated with the cutaneous lymphocyte antigen. Int Arch Allergy Immunol. 1995;107:359–362.
   PubMed Web of Science ®Google Scholar
• Berg EL, Yoshino T, Rott LS, et al. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1. J Exp Med. 1991;174:1461–1466.
   PubMed Web of Science ®Google Scholar
• Picker LJ, Treer JR, Ferguson-Darnell B, et al. Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J Immunol. 1993;150:1122–1136.
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge RC, Kieffer JD, Armerding D, et al. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 1997;389:978–981.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Iellem A, Colantonio L, et al. Localization of Th-cell subsets in inflammation: differential thresholds for extravasation of Th1 and Th2 cells. Immunol Today. 2000;21:183–186.
   PubMedGoogle Scholar
• Kieffer JD, Fuhlbrigge RC, Armerding D, et al. Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. Biochem Biophys Res Commun. 2001;285:577–587.
   PubMed Web of Science ®Google Scholar
• Tsuchiyama J, Yoshino T, Toba K, et al. Induction and characterization of cutaneous lymphocyte antigen on natural killer cells. Br J Haematol. 2002;118:654–662.
   PubMed Web of Science ®Google Scholar
• Chang S-E, Kim M-J, Lee W-S, et al. Natural killer cells in human peripheral blood and primary cutaneous natural killer cell lymphomas may express cutaneous lymphocyte antigen. Acta Derm Venereol. 2003;83:162–166.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Okano M, Chen HL, et al. Cutaneous lymphocyte antigen is expressed on memory/effector B cells in the peripheral blood and monocytoid B cells in the lymphoid tissues. Cell Immunol. 1999;197:39–45.
   PubMed Web of Science ®Google Scholar
• Armerding D, Fuhlbrigge RC, Kieffer JD, et al. Tonsillar B cells do not express PSGL-1, but a significant fraction displays the cutaneous lymphocyte antigen and exhibits effective E- and P-selectin ligand activity. Int Arch Allergy Immunol. 2001;126:78–90.
   PubMed Web of Science ®Google Scholar
• Kantele A, Savilahti E, Tiimonen H, et al. Cutaneous lymphocyte antigen expression on human effector B cells depends on the site and on the nature of antigen encounter. Eur J Immunol. 2003;33:3275–3283.
   PubMed Web of Science ®Google Scholar
• Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol. 2009;9:153–161.
   PubMed Web of Science ®Google Scholar
• Kishimoto TK, Rothlein R. Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv Pharmacol. 1994;25:117–169.
   PubMedGoogle Scholar
• Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nat Immunol. 2008;9:953–959.
   PubMed Web of Science ®Google Scholar
• Alon R, Ley K. Cells on the run: shear-regulated integrin activation in leukocyte rolling and arrest on endothelial cells. Curr Opin Cell Biol. 2008;20:525–532.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol. 2015;136:941–951.e3.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Santamaria-Babí LF, Guttman-Yassky E. Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers. Allergy. 2017;72:366–372.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015;136:104–115.e7.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Malajian D, Shemer A, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. J Allergy Clin Immunol. 2015;136:208–211.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He HY, Wen HC, et al. Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T-cell populations. Allergy Eur J Allergy Clin Immunol. 2018;73:713–723.
   Google Scholar
• Czarnowicki T, He H, Leonard A, et al. Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. J Allergy Clin Immunol. 2019;143:2095–2107.
   PubMed Web of Science ®Google Scholar
• Van Den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients: destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab. Investig. 2000;80:1299–1309.
   Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol Mosby Inc. 2017;140:645–653.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–240.
   PubMed Web of Science ®Google Scholar
• Ruiz-Romeu E, Ferran M, de Jesus-gil C, et al. Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A. J Invest Dermatol. 2018;138:580–587.
   PubMed Web of Science ®Google Scholar
• Pont-Giralt M, Gimenez-Arnau AM, Pujol RM, et al. Circulating CLA(+) T cells from acute and chronic psoriasis patients manifest a different activation state and correlation with disease severity and extension. J Invest Dermatol United States. 2006;126:227–228.
   PubMed Web of Science ®Google Scholar
• Ferran M, Romeu ER, Rincon C, et al. Circulating CLA+ T lymphocytes as peripheral cell biomarkers in T-cell-mediated skin diseases. Exp Dermatol. 2013;22:439–442.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–1211.
   PubMed Web of Science ®Google Scholar
• Schlapbach C, Gehad A, Yang C, et al. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med. 2014;6:219ra8.
   PubMed Web of Science ®Google Scholar
• Davison SC, Ballsdon A, Allen MH, et al. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol. 2001;10:280–285.
   PubMed Web of Science ®Google Scholar
• Vissers WHPM, Arndtz CHM, Muys L, et al. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol. 2004;150:852–859.
   PubMed Web of Science ®Google Scholar
• Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1–6.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg. 2010;29:3–9.
   PubMed Web of Science ®Google Scholar
• Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL, et al. Psoriasis–as an autoimmune disease caused by molecular mimicry. Trends Immunol. 2009;30:494–501.
   PubMed Web of Science ®Google Scholar
• Baker BS, Garioch JJ, Hardman C, et al. Induction of cutaneous lymphocyte-associated antigen expression by group A streptococcal antigens in psoriasis. Arch Dermatol Res. 1997;289:671–676.
   PubMed Web of Science ®Google Scholar
• Bergboer JGM, Zeeuwen PLJM, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol. 2012;132:2320–2331.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Leung DYM. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242:233–246.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract. 2014;2:371–379.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344–1354.
   PubMed Web of Science ®Google Scholar
• Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol. 1995;96:302–318. quiz 319.
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3:673–680.
   PubMed Web of Science ®Google Scholar
• Santamaria Babi LF, Picker LJ, Perez Soler MT, et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen. J Exp Med. 1995;181:1935–1940.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242:233–246.
   PubMed Web of Science ®Google Scholar
• Bunikowski R, Mielke ME, Skarabis H, et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol. 2000;105:814–819.
   PubMed Web of Science ®Google Scholar
• Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151–1160.
   PubMed Web of Science ®Google Scholar
• Kong HH, Segre JA. Skin microbiome: looking back to move forward. J Invest Dermatol. 2012;132:933–939.
   PubMed Web of Science ®Google Scholar
• Jung T, Schulz S, Zachmann K, et al. Expansion and proliferation of skin-homing T cells in atopic dermatitis as assessed at the single cell level. Int Arch Allergy Immunol. 2003;130:143–149.
   PubMed Web of Science ®Google Scholar
• Akdis M, Akdis CA, Weigl L, et al. Skin-homing, CLA+ memory T cells are activated in atopic dermatitis and regulate IgE by an IL-13-dominated cytokine pattern: igG4 counter-regulation by CLA- memory T cells. J Immunol. 1997;159:4611–4619.
   PubMed Web of Science ®Google Scholar
• Teraki Y, Hotta T, Shiohara T. Increased circulating skin-homing cutaneous lymphocyte-associated antigen (CLA)+ type 2 cytokine-producing cells, and decreased CLA+ type 1 cytokine-producing cells in atopic dermatitis. Br J Dermatol. 2000;143:373–378.
   PubMed Web of Science ®Google Scholar
• Gelb AB, Smoller BR, Warnke RA, et al. Lymphocytes infiltrating primary cutaneous neoplasms selectively express the cutaneous lymphocyte-associated antigen (CLA). Am J Pathol. 1993;142:1556–1564.
   PubMed Web of Science ®Google Scholar
• Clark WHJ, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–727.
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MCJ, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303–1310.
   PubMed Web of Science ®Google Scholar
• Mullins IM, Slingluff CL, Lee JK, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 2004;64:7697–7701.
   PubMed Web of Science ®Google Scholar
• Tuthill RJ, Unger JM, Liu PY, et al. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002;118:504–511.
   PubMed Web of Science ®Google Scholar
• Adams DH, Yannelli JR, Newman W, et al. Adhesion of tumour-infiltrating lymphocytes to endothelium: a phenotypic and functional analysis. Br J Cancer. 1997;75:1421–1431.
   PubMed Web of Science ®Google Scholar
• Rohde D, Schluter-Wigger W, Mielke V, et al. Infiltration of both T cells and neutrophils in the skin is accompanied by the expression of endothelial leukocyte adhesion molecule-1 (ELAM-1): an immunohistochemical and ultrastructural study. J Invest Dermatol. 1992;98:794–799.
   PubMed Web of Science ®Google Scholar
• Weishaupt C, Munoz KN, Buzney E, et al. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin Cancer Res. 2007;13:2549–2556.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Heidel J, Gawlik C, et al. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst. 1995;87:366–371.
   PubMedGoogle Scholar
• Nooijen PT, Westphal JR, Eggermont AM, et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol. 1998;152:679–682.
   PubMed Web of Science ®Google Scholar
• Krieg C, Boyman O. The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin Cancer Biol. 2009;19:76–83.
   PubMed Web of Science ®Google Scholar
• Clark RA, Chong BF, Mirchandani N, et al. A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol. 2006;126:1059–1070.
   PubMed Web of Science ®Google Scholar
• Jokai H, Marschalko M, Csomor J, et al. Tissue-specific homing of immune cells in malignant skin tumors. Pathol Oncol Res. 2012;18:749–759.
   PubMed Web of Science ®Google Scholar
• Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med. 2008;205:2221–2234.
   PubMed Web of Science ®Google Scholar
• Hald J, Rasmussen N, Claesson MH. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother. 1995;41:243–250.
   PubMed Web of Science ®Google Scholar
• Dummer R, Urosevic M, Kempf W, et al. Imiquimod in basal cell carcinoma: how does it work?. Br J Dermatol. 2003;149(Suppl):57–58.
   PubMedGoogle Scholar
• Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139:1325–1332.
   PubMed Web of Science ®Google Scholar
• Verhaegh M, Beljaards R, Veraart J, et al. Adhesion molecule expression in basal cell carcinoma. Eur J Dermatol. 1998;8:252–255.
   PubMed Web of Science ®Google Scholar
• Kooy AJ, Prens EP, Van Heukelum A, et al. Interferon-gamma-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10? J Pathol. 1999;187:351–357.
   PubMed Web of Science ®Google Scholar
• Kooy AJ, Tank B, Vuzevski VD, et al. Expression of interferon-gamma receptors and interferon-gamma-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN-gamma R and shedding of ICAM-1 as a means to escape immune surveillance. J Pathol. 1998;184:169–176.
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116:767–771.
   PubMed Web of Science ®Google Scholar
• Beyer M, Mobs M, Humme D, et al. Pathogenesis of Mycosis fungoides. J Dtsch Dermatol Ges. 2011;9:594–598.
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92:1085–1102.
   PubMed Web of Science ®Google Scholar
• Magro CM, Dyrsen ME. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates. J Cutan Pathol. 2008;35:1040–1049.
   PubMed Web of Science ®Google Scholar
• Lu D, Duvic M, Medeiros LJ, et al. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol. 2001;115:413–421.
   PubMed Web of Science ®Google Scholar
• Nicolay JP, Felcht M, Schledzewski K, et al. Sezary syndrome: old enigmas, new targets. J Dtsch Dermatol Ges. 2016;14:256–264.
   PubMed Web of Science ®Google Scholar
• Moins-Teisserenc H, Daubord M, Clave E, et al. CD158k is a reliable marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. J Invest Dermatol. 2015;135:247–257.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Weidner A, Olsen EA, et al. Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. Leukemia. 1993;7:859–863.
   PubMed Web of Science ®Google Scholar
• Heald PW, Yan SL, Edelson RL, et al. Skin-selective lymphocyte homing mechanisms in the pathogenesis of leukemic cutaneous T-cell lymphoma. J Invest Dermatol. 1993;101:222–226.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Nakamura S, Suzumiya J, et al. Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma. Br J Haematol. 2002;118:482–487.
   PubMed Web of Science ®Google Scholar
• von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med. 2000;343:1020–1034.
   PubMed Web of Science ®Google Scholar
• Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol. 2018;22:61–67.
   Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379:341–351.
   PubMed Web of Science ®Google Scholar
• Lin P-T, Wang S-H, Chi -C-C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8:16068.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345–356.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79:824–830.e2.
   PubMed Web of Science ®Google Scholar
• Yao Y, Ravn Jørgensen A-H, Thomsen SF. Biologics for chronic inflammatory skin diseases: an update for the clinician. J Dermatolog Treat. 2020;31:108–130.
   PubMed Web of Science ®Google Scholar
• Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140:633–643.
   PubMed Web of Science ®Google Scholar
• Vennegoor A, van Rossum JA, Leurs C, et al. High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol. 2016;23:1079–1085.
   PubMed Web of Science ®Google Scholar
• Boehncke W-H, Schon MP. Interfering with leukocyte rolling–a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci. 2003;24:49–52.
   PubMed Web of Science ®Google Scholar
• Nicolls MR, Gill RG. LFA-1 (CD11a) as a therapeutic target. Am J Transplant. 2006;6:27–36.
   PubMed Web of Science ®Google Scholar
• Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004;4:211–222.
   PubMed Web of Science ®Google Scholar
• Joshi A, Bauer R, Kuebler P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol. 2006;46:10–20.
   PubMed Web of Science ®Google Scholar
• Harper EG, Simpson EL, Takiguchi RH, et al. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J Invest Dermatol. 2008;128:1173–1181.
   PubMed Web of Science ®Google Scholar
• Krueger J, Gottlieb A, Miller B, et al. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol. 2000;115:333.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138:591–600.
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Kikuchi T, Lowes MA, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol. 2004;113:38–46.
   PubMed Web of Science ®Google Scholar
• Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006;54:S171–81.
   PubMed Web of Science ®Google Scholar
• Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 2009;1:583–589.
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies. Annu Rev Med. 2010;61:35–47.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Nguyen CV, Bohjanen KA. Skin-directed therapies in cutaneous T-cell lymphoma. Dermatol Clin W.B. Saunders. 2015;33:683–696.
   PubMed Web of Science ®Google Scholar
• Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sézary syndrome. J Clin Oncol. 2010;28:2365–2372.
   PubMed Web of Science ®Google Scholar
• Welborn M, Duvic M. Antibody-based therapies for cutaneous T-cell lymphoma. Am J Clin Dermatol Springer International Publishing. 2019;20:115–122.
   PubMed Web of Science ®Google Scholar
• Alaibac M. Monoclonal antibodies against cutaneous T-cell lymphomas. Expert Opin Biol Ther. 2017;17:1503–1510.
   PubMed Web of Science ®Google Scholar
• Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27:11–20.
   PubMed Web of Science ®Google Scholar
• Oka T, Miyagaki T. Novel and future therapeutic drugs for advanced mycosis fungoides and sezary syndrome. Front Med. 2019;6:116.
   PubMed Web of Science ®Google Scholar
• Ogawa M, Tomita Y, Nakamura Y, et al. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget. 2017;8:10425–10436.
   PubMedGoogle Scholar